Edition:
United Kingdom

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

12.42USD
23 May 2018
Change (% chg)

-- (--)
Prev Close
$12.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
58,768
52-wk High
$13.05
52-wk Low
$5.85

Latest Key Developments (Source: Significant Developments)

Recro Pharma Inc Reports Year End 2017 Financial Results
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Recro Pharma Inc ::RECRO PHARMA REPORTS YEAR END 2017 FINANCIAL RESULTS.RECRO PHARMA INC - FOR 2018, COMPANY EXPECTS REVENUE GENERATED FROM ITS CDMO DIVISION TO BE APPROXIMATELY $70 MILLION.RECRO PHARMA INC - IV MELOXICAM NDA SUBMITTED AND PDUFA ACTION DATE SET FOR MAY 26, 2018.  Full Article

Recro Pharma - ‍Ryan Lake Promoted To CFO
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Recro Pharma Inc ::RECRO PHARMA INC - ‍RYAN D. LAKE HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER​.  Full Article

Recro Pharma Says Entered Into A Sales Agreement With Cowen And Co‍​
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Recro Pharma Inc ::RECRO PHARMA INC - ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY‍​.RECRO PHARMA - PURSUANT TO AGREEMENT, CO MAY SELL FROM TIME TO TIME, COMMON STOCK SHARES, $0.01 PAR VALUE/SHARE, WITH OFFERING PRICE OF UP TO $40 MILLION.  Full Article

Recro Pharma secures $100 million credit facility
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Recro Pharma Inc :Recro Pharma Inc secures $100 million credit facility.Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​.Recro Pharma Inc - ‍proceeds from facility to refinance Recro's outstanding debt, pay $45 million milestone to alkermes upon approval of iv meloxicam 30mg by FDA​.  Full Article

Recro Pharma reports Q3 revenue $17.1 million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Recro Pharma Inc :Recro Pharma reports third quarter 2017 financial results.Q3 revenue $17.1 million versus I/B/E/S view $13.7 million.Recro Pharma Inc - ‍Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million​.Recro Pharma Inc qtrly ‍revenues were $17.1 million versus $17.0 million​.Recro Pharma Inc - ‍As of September 30, 2017, Recro had cash, cash equivalents and short-term investments of $41.3 million​.  Full Article

RECRO PHARMA ANNOUNCES PDUFA DATE OF MAY 26, 2018 FOR IV MELOXICAM 30MG
Thursday, 5 Oct 2017 

Oct 5 (Reuters) - Recro Pharma Inc ::RECRO PHARMA ANNOUNCES PDUFA DATE FOR IV MELOXICAM 30MG.RECRO PHARMA - U.S. FDA HAS SET A PDUFA DATE OF MAY 26, 2018 FOR ITS DECISION ON NEW DRUG APPLICATION (NDA) FOR INTRAVENOUS (IV) MELOXICAM 30MG.  Full Article

Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg
Thursday, 28 Sep 2017 

Sept 28 (Reuters) - Recro Pharma Inc :Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg.  Full Article

Recro Pharma quarterly ‍loss per share $0.48
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Recro Pharma Inc :Recro Pharma reports second quarter 2017 financial results.Q2 revenue $16.9 million versus i/b/e/s view $14.6 million.Qtrly ‍loss per share $0.48; Co is raising its guidance for 2017 revenue from a range of $55-$60 million to $60-$63 million​.  Full Article

Recro Pharma acquires Novel Neuromuscular blocking agents
Wednesday, 5 Jul 2017 

July 5 (Reuters) - Recro Pharma Inc :Recro Pharma acquires Novel Neuromuscular blocking agents.Says ‍under terms of agreement, Recro Pharma will pay Cornell a six figure initial up-front fee​.Recro Pharma Inc - under terms of agreement, Recro Pharma will pay Cornell a six figure initial up-front fee.Recro Pharma - ‍cornell entitled to receive additional milestone payments in millions per each acquired candidate upon achievement of certain U.S., EU regulatory approval.  Full Article

Recro Pharma files for mixed shelf‍​ of up to $100 mln - SEC Filing ‍​
Monday, 5 Jun 2017 

June 5 (Reuters) - Recro Pharma Inc :Recro pharma files for mixed shelf‍​ of up to $100 million - sec filing ‍​.  Full Article

BRIEF-Recro Pharma Reports Q1 Loss Per Share Of $0.65

* Q1 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S